CA2109829A1 - Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene - Google Patents

Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene

Info

Publication number
CA2109829A1
CA2109829A1 CA002109829A CA2109829A CA2109829A1 CA 2109829 A1 CA2109829 A1 CA 2109829A1 CA 002109829 A CA002109829 A CA 002109829A CA 2109829 A CA2109829 A CA 2109829A CA 2109829 A1 CA2109829 A1 CA 2109829A1
Authority
CA
Canada
Prior art keywords
seq
oligonucleotide
mer
myb
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002109829A
Other languages
English (en)
French (fr)
Inventor
Bruno Calabretta
Alan M. Gewirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2109829A1 publication Critical patent/CA2109829A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
CA002109829A 1991-05-23 1992-05-22 Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene Abandoned CA2109829A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70486291A 1991-05-23 1991-05-23
US704,862 1991-05-23
PCT/US1992/004318 WO1992020348A1 (en) 1991-05-23 1992-05-22 Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene

Publications (1)

Publication Number Publication Date
CA2109829A1 true CA2109829A1 (en) 1992-11-26

Family

ID=24831149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109829A Abandoned CA2109829A1 (en) 1991-05-23 1992-05-22 Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene

Country Status (4)

Country Link
EP (1) EP0585399A4 (ja)
JP (1) JPH06508130A (ja)
CA (1) CA2109829A1 (ja)
WO (1) WO1992020348A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
EP0673252A4 (en) * 1992-12-14 1998-07-15 Start Technology Partnership ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES TO THE DOPAMIN RECEPTOR RNA MESSENGER FOR DIAGNOSING AND TREATING NEUROLOGICAL CONDITIONS.
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
GB9504598D0 (en) 1995-03-03 1995-04-26 Imp Cancer Res Tech Method of nucleic acid analysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof

Also Published As

Publication number Publication date
JPH06508130A (ja) 1994-09-14
EP0585399A1 (en) 1994-03-09
WO1992020348A1 (en) 1992-11-26
EP0585399A4 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
US7022831B1 (en) Regulation of BCL-2 gene expression
US6277832B1 (en) Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1)
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
EP0722342B1 (en) REGULATION OF bcl-2 GENE EXPRESSION
JP2003524637A (ja) Ｌｎａ修飾オリゴヌクレオチドの治療上の使用
EP1135482B1 (en) Cancer cell vaccine
EP1811024A1 (en) Oligo double-stranded rna and medicinal composition
EP0668782B1 (en) Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
EP0846170B1 (en) Modified protein kinase a-specific oligonucleotides and methods of their use
CA2109829A1 (en) Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene
WO1997011171A9 (en) Modified protein kinase a-specific oligonucleotides and methods of their use
US6624293B1 (en) Modified protein kinase A-specific oligonucleotides and methods of their use
EP0667778A1 (en) Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
JPH09104629A (ja) ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
CA2223109A1 (en) Use of antisense oligonucleotides to il-6 receptor mrna to inhibit cellular proliferation
WO1998013072A1 (en) Compositions for and methods of treating multiple drug resistance
US7074768B2 (en) Modified protein kinase A-specific oligonucleotides and methods of their use
CA2126692A1 (en) Method for making universal donor cells
EP1007656B1 (en) Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use
WO1994004137A1 (en) Antisense oligonucleotides to cyclin d1 proto-oncogene
US7314927B2 (en) Regulation of bcl-2 gene expression
CA2232390A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate

Legal Events

Date Code Title Description
FZDE Dead